WVE 210201

Drug Profile

WVE 210201

Alternative Names: Exon 51 modulators - Wave Life Sciences; WVE-210201

Latest Information Update: 17 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator WaVe life Sciences
  • Class Antisense oligonucleotides
  • Mechanism of Action Dystrophin expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Duchenne muscular dystrophy

Most Recent Events

  • 16 Aug 2018 US FDA grants rare pediatric disease designation for WVE 210201 for Duchenne muscular dystrophy in USA
  • 16 Aug 2018 WVE 210201 receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 09 Aug 2018 WaVe Life Sciences planned a phase II/III trial in Duchenne muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top